After-hours trading on Wednesday saw InflaRx N.V. (NASDAQ: IFRX) shares rise 11.61%, finishing at $2.50. This spike, which comes before the firm takes part in a major industry event, indicates that investors are becoming more optimistic about the company’s prospects for the future. Moreover, IFRX has an ST score of 40 on our screener in the biotechnology industry. Visit our screener link if you’re interested in biotechnology stocks with higher scores.
InflaRx to Showcase Innovations at Guggenheim Biotech Conference
InflaRx will be attending the esteemed Guggenheim SMID Cap Biotech Conference, which will take place in New York, NY, on February 5–6, 2025. The business, which is renowned for its groundbreaking work in anti-inflammatory treatments, especially for its improvements in complement system targeting, is anticipated to showcase its most recent studies and clinical breakthroughs. The event will be eagerly watched by investors and industry professionals as it offers InflaRx a chance to strengthen its standing in the biotech industry.
EU Grants Exceptional Marketing Authorization for GOHIBIC
InflaRx has been granted permission by the European Commission (EC) to market GOHIBIC or vilobelimab under special conditions, which is a major regulatory milestone. Adult patients with COVID-induced acute respiratory distress syndrome, or ARDS, are treated with systemic corticosteroids and invasive mechanical ventilation, or IMV, with or without extracorporeal membrane oxygenation, or ECMO.
GOHIBIC, the first and only approved drug for COVID-induced acute respiratory distress syndrome in the EU, exemplifies InflaRx’s commitment to addressing critical care units’ pressing unmet medical needs. The authorization extends to Iceland, Liechtenstein, Norway, and all 27 EU countries. InflaRx is looking at local business partnerships and distribution, but the company does not anticipate that these efforts will significantly lower its capital burn rate.
Emergency Use Permission in the United States
If administered within 48 hours after the initiation of IMV or ECMO, the GOHIBIC Emergency Use Authorization (EUA) has been approved by the US Food and Drug Administration (FDA) to treat hospitalized patients with COVID-19. The EUA remains in place for the duration of the COVID-19 public health emergency, providing temporary access to this essential treatment option for healthcare providers.